Why the study?
The safety and efficacy of aspirin-free P2Y12 inhibitor monotherapy without initial DAPT compared with standard DAPT strategies following PCI required further investigation.
Does aspirin-free P2Y12 inhibitor monotherapy without initial DAPT improve safety and efficacy compared to standard DAPT strategies in patients with acute coronary syndrome or stable coronary artery disease after PCI?
Does aspirin-free P2Y12 inhibitor monotherapy without initial DAPT improve safety and efficacy compared to standard DAPT strategies in patients with acute coronary syndrome or stable coronary artery disease after PCI?
While single-arm studies suggest aspirin-free P2Y12 inhibitor monotherapy immediately after PCI is feasible, its safety and efficacy compared to standard DAPT require further investigation.
Should not yet change post-PCI DAPT practice; randomized trials needed to establish safety and efficacy of aspirin-free monotherapy.
Single-arm studies suggest the safety and feasibility of aspirin-free P2Y12 inhibitor monotherapy without initial DAPT after PCI in selected patients with acute coronary syndrome or stable coronary artery disease. However, the safety and efficacy of this aspirin-free approach compared with standard DAPT strategies following PCI still require further investigation.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: